NEW YORK, June 14 (GenomeWeb News) - Cellular Genomics has raised $34.9 million in a Series C private equity financing round, the Branford, Conn.-based company said today.
Cellular Genomics plans to use the funding to advance its drug development programs into the clinic. The company applies its chemical genetics platform both for in-house drug discovery and in collaborations with pharmaceutical and biotechnology companies, including Affymetrix, Eli Lilly, and Pfizer.
Previous investors Coastview Capital and Connecticut Innovations were joined by new investors CDP Capital, RiverVest Venture Partners, and Toucan Capital in this round.